IXICO PLC (AIM:IXI, OTC:PHYOF) said it was selected by a leading European biopharmaceutical company to provide MRI and DAT-SPECT imaging services for a phase 2 clinical trial in Parkinson's disease (PD).
Under the contract, the neuro-imaging specialist will provide radiology and quantitative analysis services to support patient selection, safety, and efficacy analysis. The trial is expected to be delivered over a period of four and a half years, it said in a statement.
This is the second study award with this client in the last 12 months, IXICO noted.
READ: IXICO PLC (AIM:IXI, OTC:PHYOF) expects strong second half; flags clinical trial impact
"We are delighted to be awarded this contract to support the development of this promising investigational drug in PD. Our success in being awarded a second study with this client, demonstrates the momentum we are building in expanding into a broader range of neurodegenerative therapeutic indications,” said CEO Giulio Cerroni.